MA35437B1 - Proteines de fusion pour le traitement de troubles du metabolisme - Google Patents

Proteines de fusion pour le traitement de troubles du metabolisme

Info

Publication number
MA35437B1
MA35437B1 MA36824A MA36824A MA35437B1 MA 35437 B1 MA35437 B1 MA 35437B1 MA 36824 A MA36824 A MA 36824A MA 36824 A MA36824 A MA 36824A MA 35437 B1 MA35437 B1 MA 35437B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
metabolic disorders
treatment
fgf21
proteins
Prior art date
Application number
MA36824A
Other languages
English (en)
Inventor
Brian R Boettcher
Shari L Caplan
Douglas S Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35437B1 publication Critical patent/MA35437B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'identification de protéines de fusion comprenant des variants de polypeptides et de protéines du facteur de croissance des fibroblastes 21 (fgf21) présentant des propriétés pharmaceutiques améliorées. L'invention concerne également des procédés de traitement de troubles associés au fgf21, y compris des troubles du métabolisme
MA36824A 2011-09-26 2014-03-13 Proteines de fusion pour le traitement de troubles du metabolisme MA35437B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
PCT/US2012/057384 WO2013049247A1 (fr) 2011-09-26 2012-09-26 Protéines de fusion pour le traitement de troubles du métabolisme

Publications (1)

Publication Number Publication Date
MA35437B1 true MA35437B1 (fr) 2014-09-01

Family

ID=46970456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36824A MA35437B1 (fr) 2011-09-26 2014-03-13 Proteines de fusion pour le traitement de troubles du metabolisme

Country Status (41)

Country Link
US (7) US9006400B2 (fr)
EP (2) EP2760475B1 (fr)
JP (4) JP6186361B2 (fr)
KR (1) KR102085605B1 (fr)
CN (2) CN107266579B (fr)
AP (1) AP2014007543A0 (fr)
AR (2) AR088044A1 (fr)
AU (1) AU2012316052A1 (fr)
BR (1) BR112014007069B1 (fr)
CA (1) CA2849464C (fr)
CL (2) CL2014000736A1 (fr)
CO (1) CO6920257A2 (fr)
CR (1) CR20140140A (fr)
CU (2) CU24314B1 (fr)
CY (2) CY1120928T1 (fr)
DK (2) DK2760475T3 (fr)
EA (1) EA039633B1 (fr)
ES (2) ES2895080T3 (fr)
GT (1) GT201400055A (fr)
HR (2) HRP20211575T1 (fr)
HU (2) HUE039857T2 (fr)
IL (1) IL231533B (fr)
IN (1) IN2014DN02043A (fr)
JO (1) JO3476B1 (fr)
LT (2) LT2760475T (fr)
MA (1) MA35437B1 (fr)
MX (1) MX350273B (fr)
MY (1) MY166059A (fr)
PE (2) PE20181159A1 (fr)
PL (2) PL3321276T3 (fr)
PT (2) PT2760475T (fr)
RS (2) RS62341B1 (fr)
SG (2) SG10201602339XA (fr)
SI (2) SI3321276T1 (fr)
SM (1) SMT202100595T1 (fr)
TN (1) TN2014000109A1 (fr)
TW (1) TWI593708B (fr)
UA (1) UA113856C2 (fr)
UY (2) UY34346A (fr)
WO (1) WO2013049247A1 (fr)
ZA (1) ZA201401700B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169984B (zh) 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
EP2857499A1 (fr) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Acides nucléiques techniques et leurs procédés d'utilisation
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
EP3798228A1 (fr) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions et procédés pour le traitement de troubles métaboliques et de maladies
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3057605A1 (fr) 2013-10-18 2016-08-24 Novartis AG Méthodes de traitement du diabete et de troubles associés
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
WO2015138278A1 (fr) * 2014-03-11 2015-09-17 Novartis Ag Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (fr) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
SG11201702757YA (en) * 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3331914A1 (fr) 2015-08-03 2018-06-13 Novartis AG Méthode de traitement des troubles associés au fgf21
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
EP3463427A4 (fr) * 2016-05-25 2020-03-11 Board of Regents, The University of Texas System Méthodes et compositions pour le traitement de troubles sécrétoires
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759697B (zh) * 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3047862A1 (fr) 2016-12-22 2018-06-28 Sanofi Combinaisons d'agonistes du compose fgf21/agoniste du glp-1r ayant un rapport d'activite optimise
WO2018166461A1 (fr) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
US11479591B2 (en) * 2017-05-05 2022-10-25 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN115109166B (zh) * 2017-11-24 2025-07-18 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109929806B (zh) 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
WO2019123427A1 (fr) * 2017-12-22 2019-06-27 Novartis Ag Procédés de traitement de troubles métaboliques avec des variants de fgf21
CN116098989B (zh) 2018-02-08 2026-03-20 广东东阳光药业股份有限公司 Fgf21变体、融合蛋白及其应用
US20210275643A1 (en) * 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (fr) * 2019-05-07 2020-11-11 Atlas Antibodies AB Formulation contenant polypeptides de fusion marques par un isotope
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
EP4076454A1 (fr) 2019-12-20 2022-10-26 Novartis AG Polythérapie de maladies hépatiques à l'aide d'inhibiteurs d'intégrine
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
US20230265152A1 (en) * 2020-07-02 2023-08-24 Sanofi Glp-1r agonist / fgf21 fusion proteins
WO2022101853A1 (fr) 2020-11-16 2022-05-19 Novartis Ag Procédé de détermination de la fibrose hépatique
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (fr) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Utilisations de protéines de fusion fgf21
WO2024102634A1 (fr) * 2022-11-07 2024-05-16 Bp Asset Ix, Inc. Variant de protéine fgf21 pour le traitement de la nash
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques
WO2024218715A1 (fr) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Milieu de culture à base d'hydrolysat de protéines et leur procédé de préparation
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN122249557A (zh) * 2023-11-23 2026-06-19 上海圆因生物科技有限公司 编码fgf21的环状rna及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
PT1232264E (pt) 1999-11-18 2009-11-26 Novartis Vaccines & Diagnostic Gene fgf-21 humano e produtos da expressão do gene
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ES2387394T3 (es) 1999-12-23 2012-09-21 Zymogenetics, Inc. Procedimiento de tratamiento de la inflamación
WO2003011213A2 (fr) 2001-07-30 2003-02-13 Eli Lilly And Company Methode de traitement du diabete et de l'obesite
EP1673395A1 (fr) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
EP2270163A1 (fr) * 2003-12-10 2011-01-05 Eli Lilly and Company Mutéines du facteur de croissance des fibroblastes
PL1751184T3 (pl) * 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
BRPI0514790A (pt) * 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP1846019A2 (fr) 2005-01-21 2007-10-24 Eli Lilly And Company Methode de traitement de maladie cardio-vasculaire
SG193860A1 (en) * 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
JP5542832B2 (ja) 2008-10-24 2014-07-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9458214B2 (en) 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
JO3476B1 (ar) * 2011-09-26 2020-07-05 Novartis Ag بروتينات مندمجة لعلاج الاضطرابات الايضية
WO2015138278A1 (fr) 2014-03-11 2015-09-17 Novartis Ag Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.

Also Published As

Publication number Publication date
CO6920257A2 (es) 2014-04-10
US20130079500A1 (en) 2013-03-28
US12527841B2 (en) 2026-01-20
HK1251238A1 (en) 2019-01-25
EP3321276B1 (fr) 2021-07-28
AR123908A2 (es) 2023-01-25
EP3321276A2 (fr) 2018-05-16
SI2760475T1 (sl) 2018-10-30
JP2018023370A (ja) 2018-02-15
DK2760475T3 (en) 2018-10-15
US20150166622A1 (en) 2015-06-18
UA113856C2 (xx) 2017-03-27
EP2760475A1 (fr) 2014-08-06
UY39119A (es) 2021-04-30
EP3321276A3 (fr) 2018-06-20
PT2760475T (pt) 2018-10-25
CN103945871B (zh) 2017-04-26
JO3476B1 (ar) 2020-07-05
AU2012316052A1 (en) 2014-04-17
CU24314B1 (es) 2018-02-08
CA2849464C (fr) 2024-01-30
JP2020007314A (ja) 2020-01-16
US11944664B2 (en) 2024-04-02
GT201400055A (es) 2017-09-28
PT3321276T (pt) 2021-10-27
HRP20211575T1 (hr) 2022-02-04
CY1124697T1 (el) 2022-07-22
CN107266579B (zh) 2022-07-12
US9006400B2 (en) 2015-04-14
CY1120928T1 (el) 2019-12-11
TW201326213A (zh) 2013-07-01
HRP20181558T1 (hr) 2018-11-30
MX2014003677A (es) 2014-04-30
ZA201401700B (en) 2015-01-28
US20180369332A1 (en) 2018-12-27
PL3321276T3 (pl) 2022-01-17
SMT202100595T1 (it) 2022-01-10
US11129874B2 (en) 2021-09-28
NZ622998A (en) 2016-07-29
CU20150171A7 (es) 2016-07-29
PE20141551A1 (es) 2014-10-26
ES2689762T3 (es) 2018-11-15
CL2016002215A1 (es) 2016-10-28
AR088044A1 (es) 2014-05-07
AP2014007543A0 (en) 2014-03-31
JP6567613B2 (ja) 2019-08-28
RS62341B1 (sr) 2021-10-29
KR102085605B1 (ko) 2020-03-06
SI3321276T1 (sl) 2021-11-30
PL2760475T3 (pl) 2018-11-30
CU24206B1 (es) 2016-10-28
JP2014534172A (ja) 2014-12-18
CL2014000736A1 (es) 2014-10-03
LT2760475T (lt) 2018-10-25
BR112014007069B1 (pt) 2020-12-15
MY166059A (en) 2018-05-22
SG11201400538QA (en) 2014-06-27
EP2760475B1 (fr) 2018-07-04
JP2022058546A (ja) 2022-04-12
PE20181159A1 (es) 2018-07-19
US10076554B2 (en) 2018-09-18
CA2849464A1 (fr) 2013-04-04
EA201490695A1 (ru) 2015-10-30
DK3321276T3 (da) 2021-10-25
US20160193297A1 (en) 2016-07-07
BR112014007069A2 (pt) 2017-03-28
RS57868B1 (sr) 2018-12-31
UY34346A (es) 2013-04-30
US9266935B2 (en) 2016-02-23
MX350273B (es) 2017-08-31
HUE055584T2 (hu) 2021-12-28
ES2895080T3 (es) 2022-02-17
TN2014000109A1 (en) 2015-07-01
CU20140034A7 (es) 2014-08-28
HUE039857T2 (hu) 2019-02-28
WO2013049247A1 (fr) 2013-04-04
KR20140069250A (ko) 2014-06-09
JP6186361B2 (ja) 2017-08-23
LT3321276T (lt) 2021-11-10
IN2014DN02043A (fr) 2015-05-15
US20260158110A1 (en) 2026-06-11
CN103945871A (zh) 2014-07-23
SG10201602339XA (en) 2016-05-30
US20240261372A1 (en) 2024-08-08
IL231533B (en) 2018-06-28
CR20140140A (es) 2014-07-15
CN107266579A (zh) 2017-10-20
TWI593708B (zh) 2017-08-01
JP7339372B2 (ja) 2023-09-05
EA039633B1 (ru) 2022-02-18
US20210386824A1 (en) 2021-12-16
IL231533A0 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MA35507B1 (fr) Protéines à double fonction pour le traitement de troubles du métabolisme
MA34710B1 (fr) Procede de traitement des troubles associes au fgf21
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
PH12018502451A1 (en) Brain delivery protein
MY183712A (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EP3192526A3 (fr) Exosomes d'administration d'agents biothérapeutiques
MX346002B (es) Anticuerpos anti-vegf y sus usos.
EA201492053A1 (ru) Белки фактора роста фибробластов 21
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders
MA37640B1 (fr) Protéines du facteur de croissance des fibroblastes 21
TH145764A (th) วิธีการสำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับ fgf21
MA37780B1 (fr) Nouveaux acides 5-aminotétrahydrochinolino-2-carboxyliques et leur utilisation
TN2010000348A1 (en) Methods and compositions using klotho-fgf fusion polypeptides